NCT05023018View on ClinicalTrials.gov

NEO100 and High-Grade Meningioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Residual, Progressive or Recurrent Grade II or III Meningioma
Interventions
DRUG

NEO100

NEO100 is a purified form of perillyl alcohol.

Trial Locations (1)

90033

RECRUITING

University of Southern California, Los Angeles

Sponsors
All Listed Sponsors
lead

Neonc Technologies, Inc.

INDUSTRY

NCT05023018 - NEO100 and High-Grade Meningioma | Biotech Hunter | Biotech Hunter